• . Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. ASCO Annual Meeting 2017(Abstract# 5032).

    ASCO Poster


  • . Targeting the N-terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. The Oncologist 2016

  • . Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino-terminal domain. JBC 2016

  • . An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. JCI Insight 2016

  • . Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. International Journal of Urology 2016